FY09 DOD Lung Cancer Promising Clinician Research Award

archived

The Lung Cancer Promising Clinician Research Award (LCPCRA) supports a research project performed by promising physician-researchers. This award is intended to prepare physicians with clinical duties and/or responsibilities for an independent and active career in lung cancer research. Previous experience in lung cancer research is allowed, but not required. However, Principal Investigators (PIs) with a limited background in lung cancer research are strongly encouraged to have a collaborator(s) who is experienced in the lung cancer field.To be eligible for this award, PIs must be in his/her first faculty appointment (either non-tenure or tenured track). PIs must demonstrate a commitment to a career in lung cancer research and clinical practice. As such, the PI is expected to commit 40% of his/her time for research. The Department of Defense (DOD) LCRP strongly encourages submissions from and partnerships with investigators at Military Treatment Facilities, Military Research Institutions, and the Department of Veterans Affairs (VA) Medical Centers and research laboratories.Areas of Emphasis: The FY09 LCPCRA mechanism ONLY accepts applications that address at least one of the seven Areas of Emphasis listed below.• Identification or development of non-invasive or minimally invasive tools to improve the detection of the initial stages of lung cancer• Identification and development of tools for screening or early detection of lung cancer. Screening may include, but is not limited to, computed tomography scans, X-rays, other imaging, biomarkers, genetics/genomics/proteomics, and assessment of risk factors• Understanding the molecular mechanisms that lead to clinically significant lung cancer• Identification of the mechanisms that lead to the development of the various types of lung cancer• Identification of innovative strategies for prevention and treatment of early lung cancer• Understanding predictive and prognostic markers to identify responders and non-responders• Understanding acquired resistance to treatmentSee the Program Announcement for the full Funding Opportunity Description.

High